Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Core Viewpoint - Innoviva Specialty Therapeutics, Inc. announced positive results from a pivotal Phase 3 trial for zoliflodacin, an investigational single-dose oral antibiotic for treating uncomplicated urogenital gonorrhea, published in The Lancet [1] Group 1 - The trial was sponsored and led by the Global Antibiotic Research & Development Partnership (GARDP), a not-for-profit partner of the company [1]